Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure

Heart-type fatty acid binding protein (H-FABP) is released into the circulation when the myocardium is injured and is a novel marker for the diagnosis of acute myocardial infarction. The purpose of the present study was to examine the clinical significance of increased serum H-FABP levels in patient...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiac failure 2005-02, Vol.11 (1), p.56-60
Main Authors: Arimoto, Takanori, Takeishi, Yasuchika, Shiga, Ryoko, Fukui, Akio, Tachibana, Hidetada, Nozaki, Naoki, Hirono, Osamu, Nitobe, Joji, Miyamoto, Takuya, Hoit, Brian D., Kubota, Isao
Format: Article
Language:English
Subjects:
Aged
Carrier Proteins - blood
Enzyme-Linked Immunosorbent Assay
Fatty Acid-Binding Proteins
Female
H-FABP
heart failure
Heart Failure - diagnosis
Humans
Male
Middle Aged
Myocytes, Cardiac - pathology
prognosis
Proportional Hazards Models
Prospective Studies
Risk Assessment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heart-type fatty acid binding protein (H-FABP) is released into the circulation when the myocardium is injured and is a novel marker for the diagnosis of acute myocardial infarction. The purpose of the present study was to examine the clinical significance of increased serum H-FABP levels in patients with congestive heart failure. Serum levels of H-FABP were measured in 179 patients admitted with congestive heart failure and 20 age-matched normal controls by using a sandwich enzyme-linked immunosorbent assay. Patients were prospectively followed during a mean follow-up period of 20 months with the end points of cardiac death and progressive heart failure requiring rehospitalization. Serum levels of H-FABP were higher in patients with congestive heart failure than in control subjects (5.7 ± 4.8 ng/mL versus 2.7 ± 0.8 ng/mL, P < .01) and increased with advancing NYHA class ( P < .01). The cardiac event rate was markedly higher in patients with elevated H-FABP levels than in those with normal levels (43% versus 7%, P < .0001). Furthermore, the Cox multivariate proportional hazard analysis revealed that the elevated H-FABP level was the only independent predictor for cardiac events (χ 2 = 7.397, P < .01). Elevation of H-FABP indicates latent and ongoing cardiomyocyte damage and identifies patients at high risk for future cardiac events in congestive heart failure.
ISSN:1071-9164
1532-8414
DOI:10.1016/j.cardfail.2004.03.005